<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7102570\results\search\drugs\results.xml">
  <result pre="cures all mice in a lethal influenza infection model, while" exact="oseltamivir" post="fails to cure the animals. Thus, favipiravir contributes to"/>
  <result pre="2009). Favipiravir shows better efficacy in treating influenza infections than" exact="oseltamivir" post="(Tamiflu) (Takahashi et al., 2003; Tanaka et al., 2017),"/>
  <result pre="Guanosine, inosine, and AICAR are biosynthesized in the body, and" exact="ribavirin" post="and ribosyl favipiravir are synthesized nucleoside analogues. They have"/>
  <result pre="influenza A(H7N9) (Li et al., 2014). A combination therapy with" exact="oseltamivir" post="has been used to treat patients with severe influenza"/>
  <result pre="and conducted experiments to compare the efficacy of favipiravir with" exact="oseltamivir" post="(Tamiflu). Based on its chemical structure, favipiravir should inhibit"/>
  <result pre="in Japan (Yasukawa, 2016) and as a combination therapy with" exact="oseltamivir" post="to treat patients with severe influenza in China (Cao,"/>
  <result pre="(EC50 = 63.7 μM) of adenine, guanine, adenosine, guanosine, and" exact="inosine" post="in the assay medium abolishes the anti-influenza virus activity"/>
  <result pre="1998; Kurokawa, Brown, Kagawa, &amp;amp; Shiraki, 2003). Cinnamyl compounds and" exact="clarithromycin" post="increase the levels of IL-12 on day 2 and"/>
  <result pre="we have experience in conducting a pharmacological study for a" exact="famciclovir" post="approval application in Japan, the efficacy and validation studies"/>
  <result pre="shows one of the comparisons of efficacy between favipiravir and" exact="oseltamivir" post="in the influenza virus infection model established with a"/>
  <result pre="of experiments, and the better efficacy of favipiravir compared with" exact="oseltamivir" post="was observed in an animal with a severe lethal"/>
  <result pre="a high viral load (Takahashi et al., 2003). Favipiravir and" exact="oseltamivir" post="show similar efficacy in low-dose infections, but the efficacy"/>
  <result pre="favipiravir as an influenza drug is clearly increased compared with" exact="oseltamivir" post="in high-titer virus infections (Fig. 3). Mice in the"/>
  <result pre="die on day 3 after a high-dose infection, and an" exact="oseltamivir" post="treatment prolongs the survival period for three days but"/>
  <result pre="infection, and all mice survive. Favipiravir exhibits better efficacy than" exact="oseltamivir" post="after a delayed administration beginning 1, 24, 48, or"/>
  <result pre="2003). Fig. 3 Comparison of the efficacy of favipiravir and" exact="oseltamivir" post="in lethal influenza virus infection. Mice were infected with"/>
  <result pre="of influenza A/PR/8/34 virus and were orally administered favipiravir and" exact="oseltamivir" post="at doses of 200 and 400 mg/kg/day for 5"/>
  <result pre="from a representative experiment. *P &amp;lt; .01 compared to 0.5%" exact="methylcellulose" post="solution-treated controls and oseltamivir-treated groups (log-rank test). The authors"/>
  <result pre="to correspond to human seasonal infection models. In this model," exact="oseltamivir" post="and favipiravir are equally effective and do not differ"/>
  <result pre="to correspond to a novel influenza infection in humans. Although" exact="oseltamivir" post="is ineffective in this model, favipiravir effectively improves survival"/>
  <result pre="macrophage-derived P388D1 cells, and the suppressive effects of favipiravir and" exact="oseltamivir" post="were compared in this P388D1 cell-based system. Favipiravir significantly"/>
  <result pre="influenza virus-infected P388D1 cells compared with the active form of" exact="oseltamivir" post="(Tanaka et al., 2017). TNF-α appears first and disappears"/>
  <result pre="effects of favipiravir treatment on alleviating influenza infection compared with" exact="oseltamivir" post="treatment. Favipiravir displays superior properties to oseltamivir in mouse"/>
  <result pre="infection compared with oseltamivir treatment. Favipiravir displays superior properties to" exact="oseltamivir" post="in mouse models, and we confirmed its efficacy in"/>
  <result pre="to the placebo in alleviating influenza symptoms and to both" exact="oseltamivir" post="and placebo in reducing the viral load 1 day"/>
  <result pre="clearance, and baloxavir-resistant viruses were not cross-resistant to favipiravir and" exact="oseltamivir" post="(Omoto et al., 2018). Baloxavir-resistant viruses were identified after"/>
  <result pre="drugs ineffective during prolonged viral growth in patients treated with" exact="oseltamivir" post="or baloxavir. Although drug-resistant viruses may have a reduced"/>
  <result pre="severe influenza infections characterized by a high viral load than" exact="oseltamivir" post="(Takahashi et al., 2003), and a favipiravir-resistant virus does"/>
  <result pre="exploited in treating patients with severe influenza in combination with" exact="oseltamivir" post="in China (Cao, 2018; Wang et al., 2019). Favipiravir"/>
  <result pre="in China (Cao, 2018; Wang et al., 2019). Favipiravir and" exact="oseltamivir" post="combination therapy accelerated clinical recovery compared to oseltamivir monotherapy"/>
  <result pre="Favipiravir and oseltamivir combination therapy accelerated clinical recovery compared to" exact="oseltamivir" post="monotherapy in severe influenza. The dose of favipiravir used"/>
  <result pre="other existing therapies is also an option and favipiravir and" exact="oseltamivir" post="combination therapy showed accelerated clinical recovery compared to oseltamivir"/>
  <result pre="and oseltamivir combination therapy showed accelerated clinical recovery compared to" exact="oseltamivir" post="monotherapy in severe influenza in China (Cao, 2018; Wang"/>
  <result pre="different from the range of 0.014–0.55 μg/mL in medium without" exact="adenosine" post="and guanosine and 10 μg/mL, respectively (Furuta et al.,"/>
  <result pre="x EC50 (63.7 μM) of adenine, guanine, adenosine, guanosine, and" exact="inosine" post="in the assay medium abolishes the anti-influenza virus activity"/>
  <result pre="strand cannot be completed. In contrast, the anti-RNA virus drug" exact="ribavirin" post="is incorporated into the replicating strand, which further elongates"/>
  <result pre="accumulates mismatched nucleotides at the incorporated sites. Base pairing with" exact="ribavirin" post="in the complementary strand during replication, transcription, and translation"/>
  <result pre="and infectious viruses with mutations in viral RdRp that affect" exact="ribavirin" post="incorporation are produced, drug-resistant viruses can be selected in"/>
  <result pre="to elongate until completion. Next, the RNA strand with multiple" exact="ribavirin" post="incorporation sites further incorporates ribavirin or serves as mRNA"/>
  <result pre="the RNA strand with multiple ribavirin incorporation sites further incorporates" exact="ribavirin" post="or serves as mRNA for viral protein synthesis. The"/>
  <result pre="serves as mRNA for viral protein synthesis. The incorporation of" exact="ribavirin" post="in the viral RNA causes the mismatch of base"/>
  <result pre="(Jin et al., 2013; Sangawa et al., 2013). Favipiravir-RTP and" exact="ribavirin" post="TP inhibit the RdRp activity in a dose-dependent manner,"/>
  <result pre="and a low IC50 (0.14 μM). On the other hand," exact="ribavirin" post="induces competitive inhibition with GTP, and incorporation results in"/>
  <result pre="incorporate labeled GTP without stopping at the incorporation site. Thus," exact="ribavirin" post="has a high IC50 value (2.4 μM) because its"/>
  <result pre="al., 2007; Talarico, Phelps, &amp;amp; Biron, 1993). Penciclovir (famciclovir) and" exact="ganciclovir" post="(valganciclovir), which are guanosine analogues, function as an anti-herpes"/>
  <result pre="activity causes a lower mutation frequency in subjects treated with" exact="penciclovir" post="and ganciclovir than in subjects treated with acyclovir. If"/>
  <result pre="a lower mutation frequency in subjects treated with penciclovir and" exact="ganciclovir" post="than in subjects treated with acyclovir. If favipiravir induces"/>
  <result pre="of favipiravir into viral RNA followed by elongation, similar to" exact="ribavirin" post="or acyclovir (Fig. 5). Favipiravir is unlikely to induce"/>
  <result pre="mutagens such as ribavirin. Ribavirin reduces GTP levels by inhibiting" exact="inosine" post="monophosphate dehydrogenase, but favipiravir has little effect on GTP"/>
  <result pre="assess the emergence of favipiravir-resistant virus, but the appearance of" exact="oseltamivir" post="or baloxavir resistance might be observed in clinical trials"/>
  <result pre="might be observed in clinical trials of influenza treatment with" exact="oseltamivir" post="and baloxavir with a similar number of patients, as"/>
  <result pre="after the start of treatment. Time from illness onset to" exact="oseltamivir" post="treatment in avian influenza A(H7N9) virus infection is 6"/>
  <result pre="respiratory tract of miceActa Virologica53200923324019941386 HawmanD.W.HaddockE.Meade-WhiteK.WilliamsonB.HanleyP.W.RosenkeK. …FeldmannH.Favipiravir (T-705) but not" exact="ribavirin" post="is effective against two distinct strains of Crimean-Congo hemorrhagic"/>
  <result pre="of Dermatological Science232000637210699766 IdaM.KageyamaS.SatoH.KamiyamaT.YamamuraJ.KurokawaM. …ShirakiK.Emergence of resistance to acyclovir and" exact="penciclovir" post="in varicella-zoster virus and genetic analysis of acyclovir-resistant variantsAntiviral"/>
  <result pre="in influenza virus-infected miceChem Pharm Bull (Tokyo)461998144414479775439 KurosakiK.MiwaN.YoshidaY.KurokawaM.KurimotoM.EndoS.ShirakiK.Therapeutic basis of" exact="vidarabine" post="on adenovirus-induced haemorrhagic cystitisAntiviral Chemistry &amp;amp; Chemotherapy15200428128515535050 LaiS.QinY.CowlingB.J.RenX.WardropN.A.GilbertM. …YuH.Global"/>
  <result pre="of Medicine370201452053223614499 LinaB.BoucherC.OsterhausA.MontoA.S.SchuttenM.WhitleyR.J.Nguyen-Van-TamJ.S.Five years of monitoring for the emergence of" exact="oseltamivir" post="resistance in patients with influenza A infections in the"/>
  <result pre="hemorrhagic feverPLoS Neglected Tropical Diseases52011e1342 MiwaN.KurosakiK.YoshidaY.KurokawaM.SaitoS.ShirakiK.Comparative efficacy of acyclovir and" exact="vidarabine" post="on the replication of varicella-zoster virusAntiviral Research652005495515652971 MoriH.ShirakiK.KatoT.HayakawaY.YamanishiK.TakahashiM.Molecular analysis"/>
  <result pre="Research1052014172124583123 OestereichL.RiegerT.LudtkeA.RuibalP.WurrS.PallaschE. …GuntherS.Efficacy of Favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, Immunocompetent mouse model of Lassa feverThe"/>
  <result pre="(H1N1) infectionFrontiers in Immunology102019216131572376 RaabeV.N.KannG.RibnerB.S.MoralesA.VarkeyJ.B.MehtaA.K. …Emory Serious Communicable DiseasesU.Favipiravir and" exact="ribavirin" post="treatment of epidemiologically linked cases of Lassa feverClinical Infectious"/>
  <result pre="fever virus infection and reduces delayed-onset neurologic disease observed with" exact="ribavirin" post="treatmentAntiviral Research1042014849224486952 ShimadaY.SuzukiM.ShirasakiF.SaitoE.SogoK.HasegawaM. …ShirakiK.Genital herpes due to acyclovir-sensitive herpes"/>
  <result pre="TakahashiK.FurutaY.FukudaY.KunoM.KamiyamaT.KozakiK. …ShirakiK.In vitro and in vivo activities of T-705 and" exact="oseltamivir" post="against influenza virusAntiviral Chemistry &amp;amp; Chemotherapy14200323524114694986 TakashitaE.EjimaM.OgawaR.FujisakiS.NeumannG.FurutaY. …OdagiriT.Antiviral susceptibility"/>
  <result pre="(IL)-12 level in the airway of mice administered orally with" exact="clarithromycin" post="or intranasally with IL-12 results in alleviation of influenza"/>
  <result pre="Jan 1434635531309975 VanderlindenE.VranckenB.Van HoudtJ.RajwanshiV.K.GillemotS.AndreiG. …NaesensL.Distinct effects of T-705 (Favipiravir) and" exact="ribavirin" post="on influenza virus replication and viral RNA synthesisAntimicrobial Agents"/>
  <result pre="implicationsVirus Research107200517318115649563 WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC. …NetworkC. A.-C.Comparative effectiveness of combined favipiravir and" exact="oseltamivir" post="therapy versus oseltamivir monotherapy in critically ill patients with"/>
  <result pre="…NetworkC. A.-C.Comparative effectiveness of combined favipiravir and oseltamivir therapy versus" exact="oseltamivir" post="monotherapy in critically ill patients with influenza virus infectionJ"/>
  <result pre="patients with influenza virus infectionJ Infect Dis2019jiz65610.1093/infdis/jiz65631822885 WestoverJ.B.SefingE.J.BaileyK.W.Van WettereA.J.JungK.H.DagleyA. …GowenB.B.Low-dose" exact="ribavirin" post="potentiates the antiviral activity of favipiravir against hemorrhagic fever"/>
  <result pre="deoxyribonucleoside triphosphate accumulation in Escherichia coliDNA Repair (Amst)420051450145616207537 WhitleyR.J.HaydenF.G.ReisingerK.S.YoungN.DutkowskiR.IpeD. …WardP.Oral" exact="oseltamivir" post="treatment of influenza in childrenThe Pediatric Infectious Disease Journal20200112713311224828"/>
 </snippets>
</snippetsTree>
